These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 31493039)
1. Level of UV Exposure, Skin Type, and Age Are More Important than Thiopurine Use for Keratinocyte Carcinoma Development in IBD Patients. Wu Y; Ghaly S; Kerr S; Jackson B; Hanigan K; Martins D; Krishnaprasad K; Mountifield RE; Whiteman DC; Bampton PA; Gearry RB; Radford-Smith GL; Lawrance IC Dig Dis Sci; 2020 Apr; 65(4):1172-1179. PubMed ID: 31493039 [TBL] [Abstract][Full Text] [Related]
2. The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines. Bahi M; Walmsley RS; Gray AR; Young D; Hobbs CE; Aluzaite K; Schultz M J Gastroenterol Hepatol; 2018 May; 33(5):1047-1052. PubMed ID: 29105142 [TBL] [Abstract][Full Text] [Related]
3. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L; Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105 [TBL] [Abstract][Full Text] [Related]
4. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825 [TBL] [Abstract][Full Text] [Related]
5. Cumulative thiopurine dosing and keratinocyte skin cancer in inflammatory bowel disease: a case-control study. Jansen FM; den Broeder N; Lubeek SFK; Savelkoul EHJ; Marcus CM; Hoentjen F; van Dop WA Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1123-1130. PubMed ID: 37665613 [TBL] [Abstract][Full Text] [Related]
6. Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature. Hagen JW; Pugliano-Mauro MA Dermatol Surg; 2018 Apr; 44(4):469-480. PubMed ID: 29315147 [TBL] [Abstract][Full Text] [Related]
7. Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Diseases Receiving Treatment With Thiopurines. Khan N; Lee H; Trivedi C; Kavani H; Medvedeva E; Xie D; Lewis JD; Yang YX Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2262-2268. PubMed ID: 30853615 [TBL] [Abstract][Full Text] [Related]
8. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD. van Gennep S; Konté K; Meijer B; Heymans MW; D'Haens GR; Löwenberg M; de Boer NKH Aliment Pharmacol Ther; 2019 Sep; 50(5):484-506. PubMed ID: 31342537 [TBL] [Abstract][Full Text] [Related]
9. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. Setshedi M; Epstein D; Winter TA; Myer L; Watermeyer G; Hift R J Gastroenterol Hepatol; 2012 Feb; 27(2):385-9. PubMed ID: 21793904 [TBL] [Abstract][Full Text] [Related]
10. Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine? Heerasing NM; Ng JF; Dowling D Intern Med J; 2016 Apr; 46(4):465-9. PubMed ID: 26425841 [TBL] [Abstract][Full Text] [Related]
11. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038 [TBL] [Abstract][Full Text] [Related]
12. Risk of nonmelanoma skin cancer with azathioprine use. Maddox JS; Soltani K Inflamm Bowel Dis; 2008 Oct; 14(10):1425-31. PubMed ID: 18383175 [TBL] [Abstract][Full Text] [Related]
13. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Ariyaratnam J; Subramanian V Am J Gastroenterol; 2014 Feb; 109(2):163-9. PubMed ID: 24419479 [TBL] [Abstract][Full Text] [Related]
14. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098 [TBL] [Abstract][Full Text] [Related]
16. [Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease]. Kim JH; Kim JW Korean J Gastroenterol; 2017 Oct; 70(4):162-168. PubMed ID: 29060953 [TBL] [Abstract][Full Text] [Related]
17. Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications. Khan N; Patel D; Trivedi C; Kavani H; Medvedeva E; Pernes T; Xie D; Lewis J; Yang YX Am J Gastroenterol; 2020 Aug; 115(8):1246-1252. PubMed ID: 32453047 [TBL] [Abstract][Full Text] [Related]
18. Inflammatory bowel disease, azathioprine and skin cancer: case report and literature review. Austin AS; Spiller RC Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):193-4. PubMed ID: 11246621 [TBL] [Abstract][Full Text] [Related]
19. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Long MD; Herfarth HH; Pipkin CA; Porter CQ; Sandler RS; Kappelman MD Clin Gastroenterol Hepatol; 2010 Mar; 8(3):268-74. PubMed ID: 20005977 [TBL] [Abstract][Full Text] [Related]
20. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]